

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1681)**

## **CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Yau Chi Ming (“**Mr. Yau**”) has resigned as the company secretary of the Company (the “**Company Secretary**”) and ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 22 August 2024.

Mr. Yau has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board further announces that following Mr. Yau’s resignation, Mr. Gao Haien (高海恩) (“**Mr. Gao**”) has been appointed as the Company Secretary and the Authorised Representative with effect from 22 August 2024.

Mr. Gao, aged 55, has been the board secretary of Guangzhou Consun Pharmaceutical Company Limited\* (“**Guangzhou Consun**”) (廣州康臣藥業有限公司) since August 2007 and the Board secretary since the listing of the Company on the Stock Exchange on 19 December 2013. Mr. Gao has been the manager and legal representative of Guangzhou Consun and Consun Pharmaceutical (Inner Mongolia) Co., Ltd.\* (“**Inner Mongolia Consun**”) (康臣藥業(內蒙古)有限責任公司) since March 2013, the manager and legal representative of Guangxi Yulin Pharmaceutical Group Co., Ltd.\* (“**Yulin Pharmaceutical**”) (廣西玉林製藥集團有限責任公司) and Guangzhou Consun Medicine Co., Ltd.\* (廣州康臣醫藥有限公司) since August 2015, a director of Yulin Pharmaceutical and Inner Mongolia Consun since August 2018, and a director and legal representative of Consun Pharmaceutical (Horgos) Co., Ltd.\* (康臣藥業(霍爾果斯)有限公司) since December 2020. Mr. Gao also acted as the joint company secretary of the Company (the “**Joint Company Secretary**”) from 15 April 2014 to 31 May 2017. Prior to joining our Group, Mr. Gao served as a general manager of the accessories store and the assistant to headquarters general manager of Shenzhen Sunyes Tools Co. Ltd.\* (深圳市新亞工具連鎖店有限公司) from January 2006 to August 2007. Between July 1995 and January 2006, Mr. Gao served as a senior engineer of IDT Data System Factory\* (萬威電子文儀廠) and a technology manager of Shenzhen Aomeidi Digital Technology Co. Ltd.\* (深圳市奧美迪數碼科技有限公司).

Mr. Gao graduated from China University of Mining and Technology\* (中國礦業大學) in July 1992 with a bachelor degree in engineering and subsequently obtained a bachelor degree in economics at the same university in January 1994. He obtained a master's degree in business administration at Zhongnan University of Economics and Law\* (中南財經政法大學) in June 2012. Mr. Gao holds Professional Certificate in Securities (Band II)\* (證券業專業水平級別證書(二級)) granted by Securities Association of China\* (中國證券業協會) and Board Secretary Certificate\* (董事局秘書資格證書) granted by the Shenzhen Stock Exchange.

Given that Mr. Gao (i) has performed his duties as Joint Company Secretary from 15 April 2014 to 31 May 2017 for more than three years with the assistance of the other Joint Company Secretary at the time, Mr. Yau (who fulfils the requirements under Rule 3.28 of the Listing Rules); (ii) has during his tenure with the Group as the then Joint Company Secretary and at his other current positions with the Group developed a good understanding of the Listing Rules and obtained relevant experience within the meaning of Rule 3.28 of the Listing Rules; and (iii) has been working with the Group for over 17 years and is very familiar with the business and operation of the Group, he is capable of discharging the duties of the Company Secretary independently. The Stock Exchange has confirmed that, by virtue of Mr. Gao's relevant experience, he is qualified to act as the Company Secretary under Rule 3.28 of the Listing Rules.

The Board would like to take this opportunity to express its gratitude to Mr. Yau for his valuable contribution to the Company during his tenure of office and to welcome Mr. Gao on his new appointment.

By Order of the Board  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 22 August 2024

*As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Ms. Chen Yujun and Professor Li Yikai as independent non-executive Directors.*

\* *for identification only*